肥厚性心肌病住院患者的心血管合并症及与较高病死率相关的因素

IF 1 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Future cardiology Pub Date : 2025-08-25 DOI:10.1080/14796678.2025.2550126

Reza Khademi, Saeed Shoar

{"title":"肥厚性心肌病住院患者的心血管合并症及与较高病死率相关的因素","authors":"Reza Khademi, Saeed Shoar","doi":"10.1080/14796678.2025.2550126","DOIUrl":null,"url":null,"abstract":"Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, with rising hospitalization rates and high comorbidity burden, yet the impact of cardiovascular comorbidities (CVC) on mortality among hospitalized HCM patients remains poorly defined.Methods: Queried the 2016 to 2020 National Inpatient Sample (NIS) to identify hospitalizations with diagnosed HCM.Results: Among 278,995 HCM hospitalizations (mean age 64.3 ± 18.4 years; 55.7% female), in-hospital mortality rose from 16.4% to 22.9% throughout the study. Cardiac arrest (41.00%), tamponade (13.70%), and ST-segment elevation myocardial infarction (STEMI) (10.20%) had the highest mortality rates. Atrial fibrillation (AF) (42.10%), heart failure with preserved ejection fraction (HFpEF) (28.10%), and cardiorenal syndrome (16.60%) were the most prevalent comorbidities. Predictors of case-fatality included increasing age (aOR: 1.02, 95% CI: 1.02-1.03, p < 0.0001), Asian/Pacific Islander race (aOR: 1.70, 95% CI: 1.10-2.40, p = 0.007), CVA (aOR: 2.30, 95% CI: 1.70-3.06, p < 0.0001), NSTEMI (aOR: 1.80, 95% CI: 1.30-2.40, p < 0.0001), cardiorenal syndrome (aOR: 1.40, 95% CI: 1.20-1.80, p < 0.001), and cardiac arrest (aOR: 26.60, 95% CI: 20.90-33.90, p < 0.001).Conclusion: Mortality rate among hospitalized HCM patients has shown a mild upward trend and is driven by age, race, NSTEMI, and cardiorenal syndrome.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-9"},"PeriodicalIF":1.0000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cardiovascular comorbidities in hospitalized patients with hypertrophic cardiomyopathy and factors associated with a higher case-fatality rate.\",\"authors\":\"Reza Khademi, Saeed Shoar\",\"doi\":\"10.1080/14796678.2025.2550126\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, with rising hospitalization rates and high comorbidity burden, yet the impact of cardiovascular comorbidities (CVC) on mortality among hospitalized HCM patients remains poorly defined.Methods: Queried the 2016 to 2020 National Inpatient Sample (NIS) to identify hospitalizations with diagnosed HCM.Results: Among 278,995 HCM hospitalizations (mean age 64.3 ± 18.4 years; 55.7% female), in-hospital mortality rose from 16.4% to 22.9% throughout the study. Cardiac arrest (41.00%), tamponade (13.70%), and ST-segment elevation myocardial infarction (STEMI) (10.20%) had the highest mortality rates. Atrial fibrillation (AF) (42.10%), heart failure with preserved ejection fraction (HFpEF) (28.10%), and cardiorenal syndrome (16.60%) were the most prevalent comorbidities. Predictors of case-fatality included increasing age (aOR: 1.02, 95% CI: 1.02-1.03, p < 0.0001), Asian/Pacific Islander race (aOR: 1.70, 95% CI: 1.10-2.40, p = 0.007), CVA (aOR: 2.30, 95% CI: 1.70-3.06, p < 0.0001), NSTEMI (aOR: 1.80, 95% CI: 1.30-2.40, p < 0.0001), cardiorenal syndrome (aOR: 1.40, 95% CI: 1.20-1.80, p < 0.001), and cardiac arrest (aOR: 26.60, 95% CI: 20.90-33.90, p < 0.001).Conclusion: Mortality rate among hospitalized HCM patients has shown a mild upward trend and is driven by age, race, NSTEMI, and cardiorenal syndrome.\",\"PeriodicalId\":12589,\"journal\":{\"name\":\"Future cardiology\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/14796678.2025.2550126\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2025.2550126","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

背景：肥厚性心肌病（HCM）是最常见的遗传性心脏疾病，住院率上升，合并症负担高，但心血管合并症（CVC）对住院HCM患者死亡率的影响仍不明确。方法：查询2016 - 2020年全国住院患者样本（NIS），确定诊断为HCM的住院情况。结果：在278,995例HCM住院患者（平均年龄64.3±18.4岁，女性55.7%）中，住院死亡率在整个研究过程中从16.4%上升到22.9%。心脏骤停（41.00%）、心包填塞（13.70%）和st段抬高型心肌梗死（10.20%）的死亡率最高。房颤（42.10%）、保留射血分数的心力衰竭（28.10%）和心肾综合征（16.60%）是最常见的合并症。病死率的预测因素包括年龄增加（aOR: 1.02, 95% CI: 1.02-1.03, p）。结论：住院HCM患者的死亡率呈轻微上升趋势，并受年龄、种族、NSTEMI和心肾综合征的驱动。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cardiovascular comorbidities in hospitalized patients with hypertrophic cardiomyopathy and factors associated with a higher case-fatality rate.

Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, with rising hospitalization rates and high comorbidity burden, yet the impact of cardiovascular comorbidities (CVC) on mortality among hospitalized HCM patients remains poorly defined.

Methods: Queried the 2016 to 2020 National Inpatient Sample (NIS) to identify hospitalizations with diagnosed HCM.

Results: Among 278,995 HCM hospitalizations (mean age 64.3 ± 18.4 years; 55.7% female), in-hospital mortality rose from 16.4% to 22.9% throughout the study. Cardiac arrest (41.00%), tamponade (13.70%), and ST-segment elevation myocardial infarction (STEMI) (10.20%) had the highest mortality rates. Atrial fibrillation (AF) (42.10%), heart failure with preserved ejection fraction (HFpEF) (28.10%), and cardiorenal syndrome (16.60%) were the most prevalent comorbidities. Predictors of case-fatality included increasing age (aOR: 1.02, 95% CI: 1.02-1.03, p < 0.0001), Asian/Pacific Islander race (aOR: 1.70, 95% CI: 1.10-2.40, p = 0.007), CVA (aOR: 2.30, 95% CI: 1.70-3.06, p < 0.0001), NSTEMI (aOR: 1.80, 95% CI: 1.30-2.40, p < 0.0001), cardiorenal syndrome (aOR: 1.40, 95% CI: 1.20-1.80, p < 0.001), and cardiac arrest (aOR: 26.60, 95% CI: 20.90-33.90, p < 0.001).

Conclusion: Mortality rate among hospitalized HCM patients has shown a mild upward trend and is driven by age, race, NSTEMI, and cardiorenal syndrome.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.